We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go: TBC investment: £127,001
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go: Extended investment: £295,000
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go: Extended investment: Withheld
Celestial Labs is a drone display company that combines advanced technology with organic performance. The company's proprietary 'Skytheatre' display is a dynamic, safe and green alternative to carbon-intensive fireworks and represents a new frontier for the live event industry. Composed of a creative collective of award-winning filmmakers, musicians, developers, entrepreneurs, and storytellers, the company is constantly pushing the boundaries of drone display innovation, where technology meets imagination. The Human Support division of Celestial is a not-for-profit initiative that aims to lift the spirits of those who witness Celestial's displays whilst imparting crucial information. The company aims to enlist the support and guidance of city leadership partners, industrial conglomerates, and seek grant funding.
days to go: Stretch investment: Withheld
Plerith works with high growth start-ups and scaling companies to plan for and deliver growth. The company asserts that it helps companies promote their business to potential funders, through its network of angel and venture capital investors depending on the stage and sector of the said business. Plerith is partnering with Newable and Bristol Private Equity Club to deliver the fund in the South West London (SWL) area and identify and invest in the most exciting high growth companies in the region. Plerith argues that its deep knowledge of fundraising, sales, strategy, finance and technology would help SWL businesses flourish. Plerith aims to provide investors access to the highest quality local companies in the SWL region.
days to go: Stretch investment: Withheld
freemarketFX is an FCA authorised, innovative peer-to-peer currency exchange, focused on the high-value B2B commercial spot FX market.
days to go: Expired investment: £645,496
Chip is a wealth investing & savings app that aims to foster financial prosperity for today's generation
days to go: Expired investment: £5,083,686
Offering a more affordable fitness class solution through training small groups and providing unparalleled client care with 1-on-1 personal training sessions. Outrivals has grown rapidly since launching 3 years ago near the famous Old Street Roundabout and are raising funds to open 2 new sites, with plans to have a portfolio of 15 branches over the next 5 years. The company has a high retention rate, with a client life cycle averaging one year.
days to go: Expired investment: £88,450
Husky is the UK’s only open, SaaS platform for workplace pensions. For employers, the platform deals with legal and compliance burdens of auto-enrolment while helping reduce pension costs. For individuals and company directors, the app is instrumental in bringing profitable and responsible investments with the Husky for Everyone app. And for advisers and accountants, it ensures strong client relationships amidst transparency and efficiency. Close to 1.4 million employers & 22.6 million workers are affected by the UK’s automatic enrolment (AE) legislation. Within this market, a conservative estimate of fees charged on employees by pension providers is £2 billion a year; Husky aims to disrupt this market & is ready to scale. Its method of operation has led to it achieving important milestones. With more than 1000 firms onboarded, a 92% renewal rate, and an average annual fee of £438, Husky charges its onboarded firms (including Crowdcube) with monthly recurring fees laid out as part of a 3-year subscription model. With the funds received, the company aims to disrupt the relatively stagnant workplace pensions industry with innovative products and empower its customers.

Pitch Rated

87%

Gold

rating powered by

CROWD RATING™

days to go: Expired investment: £417,338
AxiaFunder is a commercial litigation funding platform that offers investors access to pre-vetted cases. The platform aims to connect eligible investors like sophisticated retail investors, high-net-worth, and typically institutions with claimants seeking funding. Launched in January 2019 with the first case fully funded within seven days and the third in 7 hours; 5 cases financed to date, attracted over 355 registered investors so far including several institutions and has featured in several prominent publications including the Financial Times, Times and City AM. Also, they have won the 'Best Commercial Litigation Crowdfunding Platform 2019' award by Wealth & Finance. AxiaFunder plans to use the proceeds to make key hires particularly to strengthen its case origination, further development of its platform and marketing to build the AxiaFunder brand and grow its investor base.

Pitch Rated

72%

Overall

rating powered by

CROWD RATING™

days to go: Expired investment: £256,780
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph